Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant...

Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

Alion Canada Invests in UBC’s Naval Architecture and Marine Engineering Program OTTAWA, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Alion Canada is pleased to announce a $200,000 investment into the University of British Columbia’s (UBC) Naval Architecture and Marine Engineering (NAME)...